How Kratom, an Addictive Gas Station Drug, Gained Powerful Allies Inside President Donald Trump’s Administration

Kratom, a controversial herbal substance widely sold in U.S. gas stations, smoke shops, and convenience stores, has become the center of an intensifying political and regulatory battle after gaining influential supporters inside President Donald Trump’s administration.

The substance, derived from the leaves of the Southeast Asian tree Mitragyna speciosa, has long divided scientists, addiction specialists, lawmakers, and regulators. Supporters argue kratom helps users manage chronic pain, anxiety, and opioid withdrawal symptoms. Critics, including many public health officials, warn the drug carries significant addiction risks and can cause severe health complications.

Now, the debate has expanded beyond public health into the political arena, where several Trump administration officials and conservative allies have emerged as defenders of the rapidly growing kratom industry. (nytimes.com)

A Rapidly Expanding Industry

Kratom products are sold across much of the United States in forms including capsules, powders, gummies, and concentrated liquid extracts. Industry analysts estimate the American kratom market now generates billions of dollars annually.

Although kratom remains federally legal in most states, the U.S. Food and Drug Administration (FDA) has repeatedly warned consumers about risks associated with addiction, liver damage, seizures, contamination, and fatal overdoses involving kratom products mixed with other substances. (fda.gov)

The Drug Enforcement Administration (DEA) attempted to classify kratom as a Schedule I controlled substance in 2016 but reversed course after strong political backlash and lobbying campaigns from advocacy groups and industry organizations. (dea.gov)

Public health experts say concentrated kratom extracts sold in gas stations today are often far more potent than traditional raw leaf preparations historically used in Southeast Asia.

Trump Administration Officials Back Industry Arguments

According to investigations by The New York Times and Reuters, several officials connected to President Donald Trump’s administration have supported efforts to limit new federal restrictions on kratom products. (nytimes.com)

Industry advocates have increasingly framed kratom regulation as a matter of personal liberty, free-market policy, and opposition to federal overreach — arguments that have resonated with some conservative policymakers.

Reports indicate that political allies connected to Health and Human Services discussions and certain White House advisers have expressed skepticism toward stronger FDA enforcement efforts. Some Republican lawmakers aligned with President Donald Trump have also publicly defended kratom users and criticized what they describe as excessive federal regulation. (reuters.com)

Critics argue the industry has benefited from aggressive lobbying campaigns and political donations aimed at preventing tighter oversight.

Scientists and Addiction Experts Raise Concerns

Medical researchers remain sharply divided over kratom’s long-term effects.

The National Institute on Drug Abuse states that kratom contains compounds capable of producing both stimulant-like and opioid-like effects depending on dosage levels. Researchers say repeated use can lead to dependency and withdrawal symptoms similar to opioids in some users. (nida.nih.gov)

The FDA has linked kratom-containing products to hundreds of adverse health reports and multiple deaths, though investigators note many cases involved additional substances or contaminated products. (fda.gov)

Addiction specialists warn that concentrated kratom extracts sold in convenience stores often lack standardized dosing, quality control, or consistent labeling. Some products marketed as kratom have also been found to contain synthetic opioids or dangerous contaminants during laboratory testing. (cdc.gov)

However, some researchers argue kratom may represent a lower-risk alternative for certain opioid users if properly regulated and studied further.

States Moving in Different Directions

The absence of a unified federal policy has created a patchwork of state-level regulation.

Several states, including Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin, currently ban kratom entirely. Other states have adopted “Kratom Consumer Protection Act” laws establishing age restrictions, labeling rules, and product testing requirements. (kratomanswers.org)

Industry groups are now pushing for national standards that would preserve legal access while limiting contamination and unsafe formulations.

At the same time, public health organizations continue pressing federal agencies to strengthen oversight of products increasingly marketed in brightly packaged forms appealing to younger consumers.

Political Debate Reflects Broader Regulatory Divide

The kratom controversy increasingly reflects a broader political divide over federal health regulation, personal freedom, and the role of government oversight.

Supporters of stricter regulation argue the substance is being sold with minimal safeguards despite growing evidence of addiction and health risks. Defenders counter that banning kratom could drive users toward more dangerous opioids during an ongoing national addiction crisis.

For President Donald Trump’s administration, the issue has become another example of the difficult balance between deregulation, public health enforcement, and political alliances with emerging industries.

Federal agencies have not announced any immediate nationwide crackdown on kratom products, but lawmakers from both parties are expected to intensify scrutiny over the coming months as debates continue over addiction policy and consumer safety.